Sysmex Corporation
【Sysmex】2026 Fiscal Year Results｜Sales Decreased by 500 Billion Yen, Operating Profit of 5.1 Billion Yen
Sysmex's fiscal year ending March 2026 reported a decline in sales by 500 billion yen and an operating profit of 5.1 billion yen. Domestic sales declined by 13.5%, while overseas remained nearly flat. Net income decreased by 33.9%, and dividends increased to 38 yen. The company will promote a new medium-term management plan moving forward.
Key Figures
- Net Sales: 500,006 million yen (YoY△1.7%)
- Operating Profit: 51,831 million yen (YoY△40.8%)
- Net Income Attributable to Owners of Parent: 35,457 million yen (YoY△33.9%)
AI要約
Performance Overview
Sysmex’s fiscal year ending March 2026 reported sales of 500 billion yen, a decline of 1.7% compared to the previous year, with operating profit dropping 40.8% to 5.1 billion yen. In Japan, decreased blood testing sales impacted overall results, while overseas markets remained nearly flat, maintaining some regional growth. Net income also declined by 33.9%, and dividends increased to 38 yen. Increased R&D and selling expenses continued to suppress profits. The company has launched a new medium-term management plan to adapt to changing business environments.
Future Outlook and Strategies
Sysmex will implement a new medium-term management plan from the fiscal year ending March 2027 to March 2029, focusing on strengthening the diagnostics business and promoting healthcare DX. Although sales decline in emerging markets including China poses challenges, the launch of new products in blood coagulation and expanded overseas operations aim for sales of 535 billion yen and operating profit of 5.8 billion yen. The company is also redesigning its capital and human capital strategies to enhance corporate value.
Sysmex Corporation
Company overview · Stock price · Financial data · All IR
